Articles From: Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester to Valley National Bancorp Reports Strong Second Quarter Earnings, Increased Margin, Loan Growth And Solid Asset Quality


2014/9/8
Hosted Ribbon Cutting Ceremony for the New Bausch + Lomb ULTRA® Contact Lens Manufacturing Line and Solar Array Implementation LAVAL, Quebec , Sept.
Sign-up for Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester investment picks
2014/9/8
Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester Canada NewsWire Hosted Ribbon Cutting Ceremony for the New Bausch + Lomb ULTRA® Contact Lens Manufacturing Line and Solar Array Implementation LAVAL, Quebec , Sept.
Sign-up for Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester investment picks
LAVAL, Quebec , July 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX:VRX) announced today that it has filed a detailed complaint with the Autorite des marches financiers ("AMF") regarding Allergan, Inc.'s (NYSE: AGN) apparent attempts to mislead investors and to negatively influence the market price of Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting this misinformation.
Sign-up for Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements investment picks
Bausch + Lomb's Organic Growth 12% for the Second Quarter of 2014, over 90% Due to Volume Allergan Stockholders Encouraged to Call Special Meeting Valeant to Announce Second Quarter 2014 Financial Results on July 31, 2014 LAVAL, Quebec , July 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has filed an investor presentation with the Securities and Exchange Commission that will be used in meetings with Allergan's institutional investors and proxy advisors, the first of which is being held today, regarding calling a special meeting.
Sign-up for Valeant Pharmaceuticals Files Investor Presentation investment picks
Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino Canada NewsWire QUEBEC , Aug.
Sign-up for Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino investment picks
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results Canada NewsWire LAVAL, Quebec , July 31, 2014 /CNW/ -- 2014 Second Quarter Total Revenue $2.0 billion ; an increase of 86% over the prior year Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% 2014 Second Quarter GAAP EPS $0.37 ; Cash EPS $1.91 , an increase of 43% 2014 Second Quarter GAAP Operating Cash Flow $376 million ; Adjusted Operating Cash Flow $500 million Highlights of the Second Quarter Launched 17 new products in the U.S. year-to-date Sold facial injectable assets to Galderma S.A. for approximately $1.4 billion ; $300+ million gain Proceeds will be used to fund Allergan and/or deploy on additional business development opportunities Received FDA approval for Jublia® earlier than expected; stronger than
Sign-up for Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results investment picks
LAVAL, Quebec , July 31, 2014 /PRNewswire/ -- 2014 Second Quarter Total Revenue $2.0 billion ; an increase of 86% over the prior year Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% 2014 Second Quarter GAAP EPS $0.37 ; Cash EPS $1.91 , an increase of 43% 2014 Second Quarter GAAP Operating Cash Flow $376 million ; Adjusted Operating Cash Flow $500 million Highlights of the Second Quarter Launched 17 new products in the U.S. year-to-date Sold facial injectable assets to Galderma S.A. for approximately $1.4 billion ; $300+ million gain Proceeds will be used to fund Allergan and/or deploy on additional business development opportunities Received FDA approval for Jublia® earlier than expected; stronger than anticipated label Reached agreement with Irish Government and Unions to successfully restructure
Sign-up for Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results investment picks
LAVAL, Quebec , July 14, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan, Inc. (NYSE: AGN) .
Sign-up for Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan investment picks
LAVAL, Quebec , June 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that, as promised, it has posted fact-based answers to refute misleading assertions made by Allergan, Inc. (NYSE: AGN) in its June 10 th presentation.
Sign-up for Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements investment picks
Valener and Gaz Métro - Fiscal 2014 third quarter results release and conference call Canada NewsWire MONTRÉAL, July 16, 2014 /CNW Telbec/ - Valener Inc. ("Valener") (TSX: VNR) , the public investment vehicle in Gaz Métro Limited Partnership ("Gaz Métro"), will hold a conference call on Friday, August 8, 2014 to discuss its results and those of Gaz Métro for the third quarter ended June 30, 2014 .
Sign-up for Valener and Gaz Métro - Fiscal 2014 third quarter results release and conference call investment picks
Valener declares its quarterly dividends Canada NewsWire MONTREAL , Aug.
Sign-up for Valener declares its quarterly dividends investment picks
2014/7/29
SAN ANTONIO , July 29, 2014 /PRNewswire/ -- The Board of Directors of Valero Energy Corporation (NYSE: VLO, "Valero") has approved an increase in the company's regular quarterly cash dividend on common stock from $0.25 per share to $0.275 , effective with the quarterly dividend the Board has declared to be payable on September 17, 2014 to holders of record at the close of business on August 20, 2014 .
Sign-up for Valero Energy Corporation Increases Regular Cash Dividend on Common Stock investment picks
2014/7/14
SAN ANTONIO , July 14, 2014 /PRNewswire/ -- Valero Energy Corporation (NYSE: VLO, "Valero") announced today that the company expects to report income from continuing operations in the range of $1.10 to $1.25 per share for the second quarter of 2014.
Sign-up for Valero Energy Corporation Provides Second Quarter 2014 Interim Update investment picks
SAN ANTONIO , June 30, 2014 /PRNewswire/ -- Valero Energy Corporation (NYSE: VLO) today announced that it will host a conference call on July 30, 2014 at 9:00 a.m. CT to discuss second quarter earnings results, which will be released earlier that day, and provide an update on company operations.
Sign-up for Valero Energy Corporation to Announce Second Quarter 2014 Earnings Results on July 30, 2014 investment picks
2014/7/15
SAN ANTONIO , July 15, 2014 /PRNewswire/ -- The Board of Directors of Valero Energy Partners GP LLC, the general partner of Valero Energy Partners LP (NYSE: VLP, the Partnership), has approved the Partnership's second quarter 2014 cash distribution of $0.2225 per unit.
Sign-up for Valero Energy Partners LP Increases Quarterly Cash Distribution investment picks
2014/8/11
SAN ANTONIO , Aug.
Sign-up for Valero Energy Partners LP Reports Second Quarter 2014 Results investment picks
SAN ANTONIO , July 17, 2014 /PRNewswire/ -- Valero Energy Partners LP (NYSE:VLP) today announced that it will host a conference call on August 11, 2014 at 3:00 p.m. ET to discuss second quarter earnings results, which will be released earlier that day, and provide an update on partnership operations.
Sign-up for Valero Energy Partners To Announce Second Quarter 2014 Earnings Results on August 11, 2014 investment picks
2014/7/30
SAN ANTONIO , July 30, 2014 /PRNewswire/ -- Valero Energy Corporation (NYSE: VLO, "Valero") today reported net income from continuing operations attributable to Valero stockholders of $651 million , or $1.22 per share, for the second quarter of 2014 compared to $463 million , or $0.84 per share, for the second quarter of 2013.
Sign-up for Valero Energy Reports Second Quarter 2014 Results investment picks
NEW YORK (MarketWatch) -- Valero Energy Corp.
Sign-up for Valero tops second-quarter revenue estimates, shares rise investment picks
2014/9/3
ValidSoft is World's First Security Software Company to Achieve Four 'EuroPriSe' Privacy Seals LONDON , Sept.
Sign-up for ValidSoft Receives Unprecedented 4th European Privacy Seal for its Zero Latency Correlation (Valid-ZLC®) Technology investment picks
2014/7/24
Validus Holdings, Ltd.
Sign-up for Validus Announces Second Quarter 2014 Net Income of $153.4 Million investment picks
2014/6/23
Validus Holdings, Ltd.
Sign-up for Validus Holdings to Acquire Western World Insurance Group investment picks
2014/7/29
Validus Holdings, Ltd.
Sign-up for Validus Holdings, Ltd. Announces Quarterly Dividend investment picks
2014/8/14
Validus Holdings, Ltd.
Sign-up for Validus Holdings, Ltd. To Participate in the 2014 KBW Insurance Conference on September 3, 2014 investment picks
2014/9/10
Validus Holdings, Ltd.
Sign-up for Validus Holdings, Ltd. to Release Third Quarter 2014 Financial Results on October 29, 2014 investment picks
VISALIA, Calif.
Sign-up for Valley Commerce Bancorp Reports Earnings For Second Quarter 2014 investment picks
Nuance Communications, Inc. (NASDAQ: NUAN) announced today that Valley Medical Center, part of the University of Washington Medical Center, has achieved higher levels of clinical excellence and gained additional revenue through proper reimbursements thanks to Nuance Clintegrity 360 solutions.
Sign-up for Valley Medical Center Implements Nuance Clintegrity CDI to Drive Clinical Excellence and Generate a $2.2 Million Gain in Appropriate Revenue investment picks
WAYNE, N.J. , July 30, 2014 /PRNewswire/ -- Valley National Bancorp (NYSE: VLY) , the holding company for Valley National Bank, today reported net income for the second quarter of 2014 of $29.5 million , or $0.15 per diluted common share as compared to the second quarter of 2013 earnings of $33.9 million , or $0.17 per diluted common share.
Sign-up for Valley National Bancorp Reports Strong Second Quarter Earnings, Increased Margin, Loan Growth And Solid Asset Quality investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester to Valley National Bancorp Reports Strong Second Quarter Earnings, Increased Margin, Loan Growth And Solid Asset Quality
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices